Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7?36 amide] after subcutaneous injection in healthy volunteers. Dose-response-relationships-Reference-Cited by-同舟云学术

Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7?36 amide] after subcutaneous injection in healthy volunteers. Dose-response-relationships

Published:1995-06 Issue:6 Volume:38 Page:720-725
ISSN:0012-186X
Container-title:Diabetologia
language:en
Short-container-title:Diabetologia

Author:

Ritzel R.,�rskov C.,Holst J. J.,Nauck M. A.

Publisher

Springer Science and Business Media LLC

Subject

Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://link.springer.com/content/pdf/10.1007/BF00401846.pdf

Reference21 articles.

1. Ørskov C (1992) Glucagon-like peptide-1, a new hormone of the entero-insular axis. Diabetologia 35: 701?711

2. Creutzfeldt W, Nauck M (1992) Gut hormones and diabetes mellitus. Diabetes Metab Rev 8: 149?177

3. Kreymann B, Ghatei MA, Williams G, Bloom SR (1987) Glucagon-like peptide 1 7?36: a physiological incretin in man. Lancet II: 1300?1304

4. Nauck M, Bartels E, Ørskov C, Ebert R, Creutzfeldt W (1993) Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide 1 [7?36 amide] infused at near-physiological insulinotropic hormone and glucose concentrations. J Clin Endocrinol Metab 76: 912?917

5. Nauck MA, Heimesaat MM, Ørskov C, Holst JJ, Ebert R, Creutzfeldt W (1993) Preserved incretin activity of glucagon-like peptide 1 (GLP-1) [7?36 amide] but not of synthetic human gastric inhibitory polypeptide (GIP) in patients with type 2 diabetes mellitus. J Clin Invest 91: 301?307

Cited by 215 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. GLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management;Nature Metabolism;2024-08-19

2. Randomised comparison of intravenous and subcutaneous routes of glucagon‐like peptide‐1 administration for lowering plasma glucose in hyperglycaemic subjects with type 2 diabetes;Diabetes, Obesity and Metabolism;2024-07

3. Glucagon-Like Peptide 1 Therapy: From Discovery to Type 2 Diabetes and Beyond;Endocrinology and Metabolism;2023-02-28

4. Beneficial metabolic effects of recurrent periods of beta‐cell rest and stimulation using stable neuropeptide Y1 and glucagon‐like peptide‐1 receptor agonists;Diabetes, Obesity and Metabolism;2022-08-11

5. Naturally occurring mutations in G protein-coupled receptors associated with obesity and type 2 diabetes mellitus;Pharmacology & Therapeutics;2021-11